Combination therapies: The next logical Step for the treatment of synucleinopathies?
Year: 2015
Type: review
Abstract: Currently there are no disease-modifying alternatives for the treatment of most neurodegenerative disorders. The available therapies for diseases such as Parkinson's disease (PD), PD dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), in which the protein alpha-synuclein (α-Syn) accumulates within neurons and glial cells with toxic consequences, are focused on managing the disease symptoms. However, using strategic drug combinations and/or multi-target drugs might increase the treatment efficiency when compared with monotherapies. Synucleinopathies are complex disorders that progress through several stages, and toxic α-Syn aggregates exhibit prion-like behavior spreading from cell to cell. Therefore, it follows that these neurodegenerative disorders might require equally complex therapeutic approaches to obtain significant and long-lasting results. Hypothetically, therapies aimed at reducing α-Syn accumulation and cell-to-cell transfer, such as immunotherapy against α-Syn, could be combined with agents that reduce neuroinflammation with potential synergistic outcomes. Here we review the current evidence supporting this type of approach, suggesting that such rational therapy combinations, together with the use of multi-target drugs, may hold promise as the next logical step for the treatment of synucleinopathies.
Source: Movement Disorders
DOI: 10.1002/mds.26428
Authors: Elvira Valera, Eliezer Masliah
Institution: University of California San Diego
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Pathogenesis and Diagnosis of Multiple System Atrophy (P01), Gene Therapy for Alzheimer's Disease, La Jolla Interdisciplinary Neuroscience Center Cores, Mechanisms of Neuroprotection in HIV Encephalitis, a-synuclein clearance strategies for the treatment of Lewy body disease, a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease, UCSD Alzheimer's Disease Research Center P50, La Jolla Interdisciplinary Neuroscience Center Cores, Pathophysiology of Dystonia, G486772123, Proteinopathies of the Aging Central Nervous System, Clearance Pathways in the CNS in Aging and HIV, G9000035899, HIV Neurobehavioral Research Center
OpenAlex ID: W2128526467
